• Pfizer Inc., of New York, said the FDA accepted for review a supplemental new drug application for Xeljanz (tofacitinib citrate) seeking to expand the drug's rheumatoid arthritis (RA) indication to include inhibition of progression of structural damage. The PDUFA date is expected to be in February 2014.